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Abstract
Introduction: Treatment of rectal cancer requires a multidisciplinary approach with standardized
surgical, pathological and radiotherapeutic procedures. Sphincter preserving surgery for cancer of
the lower rectum needs a long-course of neoadjuvant treatments to reduce tumor volume, to
induce down-staging that increases circumferential resection margin, and to facilitate surgery.
Aim: To evaluate the rate of anal sphincter preservation in low lying, resectable, locally advanced
rectal cancer and the resectability rate in unresectable cases after neoadjuvent chemoradiation by
oral Capecitabine.
Patients and methods: This trial included 43 patients with low lying (4–7 cm from anal verge)
locally advanced rectal cancer, of which 33 were resectable. All patients received preoperative
concurrent chemoradiation (45 Gy/25 fractions over 5 weeks with oral capecitabine 825 mg/m2
twice daily on radiotherapy days), followed after 4–6 weeks by total mesorectal excision technique.
Results: Preoperative chemoradiation resulted in a complete pathologic response in 4 patients
(9.3%; 95% CI 3–23.1) and an overall downstaging in 32 patients (74.4%; 95% CI 58.5–85). Sphincter
sparing surgical procedures were done in 20 out of 43 patients (46.5%; 95% CI 31.5–62.2). The
majority (75%) were of clinical T3 disease. Toxicity was moderate and required no treatment
interruption. Grade II anemia occurred in 4 patients (9.3%, 95% CI 3–23.1), leucopenia in 2 patients
(4.7%, 95% CI 0.8–17) and radiation dermatitis in 4 patients (9.3%, 95% CI 3–23.1) respectively.
Conclusion:  In patients with low lying, locally advanced rectal cancer, preoperative
chemoradiation using oral capecitabine 825 mg/m2, twice a day on radiotherapy days, was tolerable
and effective in downstaging and resulted in 46.5% anal sphincter preservation rate.
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Background
Management of rectal cancer requires multidisciplinary
treatment with standardized surgical, pathological and
radiotherapeutic procedures [1,2]. Preoperative chemora-
diation is considered the preferred treatment option for
locally advanced rectal cancer (LARC) to reduce the inci-
dence of local recurrence. This option is based on the
knowledge that irradiation before surgery is more dose-
and cost-effective than postoperative irradiation and less
toxic. [3-5]. Sphincter preserving surgery for cancer of the
lower rectum needs a long-course of neoadjuvant treat-
ments to reduce tumor volume, to induce downstaging
that increases circumferential resection margin, and to
facilitate surgery [6].
Capecitabine is a fluoropyrimidine carbamate designed to
generate 5-flurouracil (5-FU) preferentially in tumor cells
as concentration of the key enzyme thymidine phosphor-
ylase is higher in tumor cells compared with normal tis-
sue. In preclinical studies, irradiation with thymidine
phosphorylase was found to be upregulated in tumor tis-
sue resulting in a supra-additive effect of capecitabine on
radiotherapy [7-9]. Capecitabine is administered daily to
mimic a continuous infusion of 5-FU [10].
Beyond the increase in convenience of using oral agents,
data from phase II studies showed that the combination
of preoperative capecitabine and radiotherapy in patients
with LARC has significant anti-tumor activity, efficacy,
and a low toxicity profile. These trials provide a clear
rationale for replacing infusional 5-FU with oral capecit-
abine as part of chemoradiation [11,12].
Patients and methods
This phase II trial included 43 patients and was conducted
from March 2006 to September 2008 at Surgical Oncol-
ogy Department and Radiotherapy Department, South
Egypt Cancer Institute, Assiut University, Egypt. This
includes all new patients admitted to these departments
during this period.
All patients underwent a complete clinical examination,
including digital rectal examination (DRE), a chest X-ray,
an abdomino-pelvic computed tomography (CT), a tran-
srectal ultrasound (TRUS) and a colonoscopy. Laboratory
studies include: complete blood count (CBC), kidney
function tests, complete liver functions, random blood
sugar, and coagulation profile. All patients underwent
treatment with curative intent for a histologically con-
firmed adenocarcinoma of the rectum. Informed consent
was taken from the patients and the study was approved
by the institutional ethics committee.
Inclusion criteria
• Patients with lower third rectal carcinoma (within 4–
7 cm of the anal verge using colonoscopy) with no
clinical evidence of distant metastases
￿ Patients with T3–T4, N0 – N1 disease
￿ Patients with a performance status ≤ 2 according to
the Eastern Cooperative Oncology Group (ECOG) sys-
tem.
Exclusion criteria
￿ Previous pelvic irradiation therapy
￿ Previous history of malignant disease
￿ Any other serious illness and/or major organ dys-
function
￿ Pregnancy or lactation.
Primary endpoints were grade of tumor downstaging and
rate of sphincter preservation. Downstaging was assessed
by comparing clinical stage and postchemoradiation
pathologic stage. Secondary end points were toxicity and
postoperative complications. Toxicity was scored accord-





￿ Target volume: included the rectum and the draining
lymph node chains (pararectal, hypogastric, presacral
lymph nodes) and was defined using the simulator. Target
volume was localized with the patient in the prone posi-
tion with a full bladder (to displace the small bowel ante-
riorly and superiorly). In the simulator, barium was
introduced into the rectum and a wire marker was placed
on the anal margin. Postero-anterior and lateral simulator
films were taken. The contour of the pelvis was marked on
the CT transverse section. The superior border of the target
volume was placed at L5/S1 interspace, the inferior border
at or distal to the obturator foramen and the lateral bor-
ders 1.5 cm outside the true bony pelvis. The anterior bor-
der was placed behind the symphysis pubis and the
posterior border was placed 2 cm behind the sacrum.
￿ Field arrangement: Three field techniques were used
(one posterior and two opposing wedged lateral fields) to
give a homogeneous distribution to the target volume.
￿ Dose and energy: All patients were treated by a photon
beam of either 6 or 15 MeV generated from a linear accel-
erator (Siemens Mevatron). The dose was 45 Gray in 25World Journal of Surgical Oncology 2009, 7:52 http://www.wjso.com/content/7/1/52
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fractions over 5 weeks prescribed at the isocenter of the
plan according to ICRU report No. 50.
Chemotherapy
Capecitabine was administered orally at a dose of 825 mg/
m2 twice a day only on radiotherapy days. The first daily
dose was given two hours before radiotherapy and the sec-
ond dose twelve hours later. Dose modifications were
applied if the patient experienced any grade 3 or 4 haema-
tological toxicity or any grade 3 nonhaematological toxic-
ity, such as hand-foot syndrome, except for alopecia.
Evaluation
Approximately 4–6 weeks after completion of chemo-
radiation, physical examination, laboratory investigation
and radiological studies (including CT scan of pelvis and
abdomen) were preformed to evaluate patients for the
possibility of surgery.
Surgical procedure
According to the protocol of the study, surgery was per-
formed 4–6 weeks after the end of preoperative chemora-
diation. All operations were performed by a total
mesorectal excision technique which involves en-bloc
resection of the rectum, perirectal fat and lymphoid tissue
[13].
The decision to perform a low anterior resection versus an
abdominoperinal resection depended on the distance of
the lesion (after preoperative chemoradiation) from the
anal verge and whether there was sphincter infiltration or
not.
After histopathologic examination of the surgical speci-
mens, rectal cancer regression grade (RCRG) was assessed,
according to Wheeler et al. (2004) [14]. The three grades
of RCRG are
￿ RCRG 1: Sterilization or only microscopic foci of
adenocarcinoma with marked fibrosis
￿ RCRG 2: Marked fibrosis but macroscopic disease
present.
￿ RCRG 3: Little or no fibrosis with abundant macro-
scopic disease.
Statistical methods
Kaplan-Meier estimates of survival and local recurrence
free survival were estimated.
Results
Forty three patients with a lower third rectal cancer were
included at this study; median age was 65 years old.
Twenty eight patients were males and 15 patients were
females with male to female ratio of 1.9: 1. Patients with
T4N1 rectal cancer were considered unresectable (by pelvic
CT scan) at presentation due to infiltration of the distal
sacrum (in 3 patients), bladder neck infiltration (in 4
patients) and vaginal infiltration (in 3 patients). All
patients and tumor characteristics are summarized in
table 1.
Evaluation of the response to preoperative chemoradia-
tion was presented in table 2. A complete pathologic
response was found in 4 patients (9.3%, 95% CI 3–23.1).
Overall downstaging was achieved in 32 patients (74.4%,
95% CI 58.5–85). No tumor progression had been
observed. Postoperative pathologic assessment showed
that T0 disease was observed in 4 patients (9.3%), T1 in 11
patients (25.6%), T2  in 8 patients (18.6%), T3  in 11
patients (25.6%), and T4 in 9 patients (20.9%).
The majority of patients (26 patients; 60.5%), were classi-
fied as RCRG2 (table 3), while only 4 patients (9.3%)
showed RCRG1, and 13 patients (30.2%) showed
RCRG3. Seven out of 11 patients (64%) with ypT3 tumor
were classified as RCRG2.
The overall sphincter preservation rate in the present
study was 46.5% (20 out of 43 patients; 95% CI 31.5–
62.2). Sphincter sparing surgical procedures were done in
the majority of patients with clinical T3 rectal cancer (15
out of 20 patients; 75%), and in only 5 out of 23 (21.7%)
patients with clinical T4 disease, 19 patients underwent
abdominoperineal resection. Four patients with c T4N1
rectal cancer, showed no response to chemoradiation












Performance status, No. (%)
0 33 (76.7)
1 10 (23.3)
Distance from anal verge:
Median (cm) 5.5
0 – <5 cm, No. (%) 16 (37.2)
5 – ≤ 7 cm, No. (%) 27 (62.8)World Journal of Surgical Oncology 2009, 7:52 http://www.wjso.com/content/7/1/52
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(ypT4N1 disease) and were considered unresectable dur-
ing exploration because of tumor infiltration of the distal
sacrum (in one patient), and presence of peritoneal
deposits (in 3 patients). In those patients, palliative colos-
tomy was done and biopsies from primary tumor and per-
irectal lymph nodes were taken. Sphincter preservation
was achieved in the majority of patients with an initial
tumor located 5 – ≤ 10 cm from anal verge (15 out of 27
patients; 55.6%) and in only 5 out of 16 patients (31.3%)
with tumor located <5 cm. After a median follow up of 25
months (range 12–30 months), the 2 year overall survival
was 79% (Fig. 1). There was only one patient out of 39
patients who underwent surgical resection due to local
recurrence (2.5%), 18 months after treatment. This
patient was reoperated for surgical resection of the recur-
rent tumor. The 2 year recurrence free survival rate was
75% (Fig. 2).
Toxicity was moderate and summarized in table 4. No
hematological grade 3 or 4 toxicities occurred. Hemato-
logical toxicity was mild with grade II anemia in 4 patients
(9.3%, 95% CI 3–23), and grade II leucopenia in 2
patients (4.7%, 95% CI 0.8–17). Regarding non hemato-
logical toxicity; hand-foot syndrome occurred only in one
patient at the end of the treatment and required no treat-
ment interruption. Grade II radiation dermatitis and
diarrhea occurred in 4 patients (9.3%, 95% CI 3–23.1)
and one patient (2.3%, 95% CI 0.1–13.8), respectively.
After completion of chemoradiation, sphincter conserv-
ing surgery was successfully performed in 20 patients
(LAR in 19 patients and CAA in one patient, using hand-
sewn technique in 14 patients and staplers in 6 patients,
(due to short distal segment in 5 patients with lesions <5
cm from anal verge and narrow pelvis in one patient with
lesions located 5–<10 cm from anal verge). Because of
diabetes mellitus and atherosclerotic changes of
mesenteric arteries, protective proximal stoma (colos-
tomy) was applied in 3 patients. Nineteen patients under-
went abdominoperineal resection. The circumferential
resection margin was free in all cases. The postoperative
30 day mortality was not observed. Postoperative morbid-
ity (10%) was in the form of anastomotic leakage (in one
out of 20 patients; 5%), which healed conservatively and
severe chest infection in one out of 20 patients; 5% (who
underwent sphincter sparing surgery) and improved with
broad spectrum antibiotics.
Table 2: Distribution of clinical tumor stage compared with postchemoradiation pathologic stage.
Clinical staging Postchemoradiotherapy pathologic (yp) staging Total (%)
ypT0N0 ypT1N0 ypT1N1 ypT2N0 ypT2N1 ypT3N0 ypT3N1 ypT4N0 ypT4N1
c T3 N0 4 1 0 0 0 0 0 0 0 5 (11.6)
c T3 N1 046030200 1 5  ( 3 4 . 9 )
c T4 N0 000503050 1 3  ( 3 0 . 2 )
c T4 N1 000000604 1 0  ( 2 3 . 3 )
Total (%) 4 (9.3) 5 (11.6) 6 (14) 5 (11.6) 3 (7) 3 (7) 8 (18.6) 5 (11.6) 4 (9.3) 43 (100)
Table 3: Pathologic T stage compared with RCRG following chemoradiation
RCRG Postchemoradiotherapy pathologic (yp) staging Total
ypT0 ypT1 ypT2 ypT3 ypT4 No. % (CI)
1 4 0000 4 9 . 3  ( 3 . 0 – 2 3 . 1 )
2 0 11 8 7 0 26 60.5 (44.5–74.7)
3 0 0049 1 3 3 0 . 2  ( 1 7 . 6 – 4 6 . 3 )
Total (%) 4 (9.3) 11 (25.6) 8 (18.6) 11 (25.6) 9 (20.9) 43 100World Journal of Surgical Oncology 2009, 7:52 http://www.wjso.com/content/7/1/52
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Discussion
The gold standard treatment for locally advanced rectal
cancer is neoadjuvant chemoradiotherapy using 5-FU
[15]. Because of the short half-life of 5-FU in plasma, it
should be given during the course of fractionated radio-
therapy in the form of prolonged intravenous infusions
which is better tolerated than a bolus administration
[16,17]. However, capecitabine (an oral fluoropyrimidine
that mimics continuously infused 5-FU) can replace intra-
venous 5-FU and may further enhance efficacy and toler-
ability. Capecitabine generates 5-FU preferentially at the
tumor site by increasing the higher activity of the enzyme
thymidine phosphorylase in tumor tissue compared with
the healthy tissue [7]. Therefore, exposure of normal tis-
sues to 5-FU within the radiation field is likely to be lower
with oral capecitabine compared with intravenous 5-FU.
Capecitabine also has proven activity as both adjuvant
and first line treatment for colorectal cancer. The results
from two large, randomized phase III trials including over
1200 patients showed that oral capecitabine was more
active than bolus 5-FU/LV in terms of tumor response
(26% versus 17%), and produced at least equivalent time
to disease progression and overall survival [11].
In a study on cost effectiveness for preoperative staging of
rectal cancer,[18] evaluation with abdominal CT plus
endorectal ultrasound (EUS) was found to be the most
cost-effective approach compared with abdominal CT
plus pelvic MRI and CT alone. Because EUS can delineate
the layers of the rectal wall, it is superior to CT in staging
accuracy. EUS and MRI can be used as complementary
methods in the preoperative staging of rectal cancer. EUS
is more accurate in determining bowel wall penetration of
the tumor, while MRI is comparable to EUS in the evalu-
ation of lymph node involvement [19,20]. In the present
study, the preoperative staging of rectal cancer was done
by using abdominopelvic CT scan and EUS.
In light of the proven efficacy and safety benefits of the
oral fluoropyrimidine capecitabine over bolus intrave-
nous 5-FU/LV in the treatment of metastatic colorectal
cancer and early stage colon cancer, a number of studies
are evaluating capecitabine as a replacement for 5-FU/LV
in chemoradiation schedules for patients with rectal can-
cer, (table 5). Beyond the increase in convenience of using
oral agents, there is also a clear rationale for improved effi-
cacy, and a reduction in the toxicity associated with radi-
otherapy [11].
The comparison of initial diagnosis and pathological
findings showed downstaging in 32 patients (74.4%),
The two year overall survival Figure 1
The two year overall survival. NB. After a median follow 
up of 25 months, the 2 year survival was 79%.
The two year recurrence free survival Figure 2
The two year recurrence free survival. NB. The 2 year 
recurrence free survival rate was 75%.
Table 4: Acute toxicity of preoperative chemoradiation
Toxicity Grade I Grade II
No (CI)% No (CI)%
Anemia 4 9.3 (3.0–23.1)
Thrombocytopenia 10 23.3 (12.3–39.0)
Leucopenia 10 23.3 (12.3–39.0) 2 4.7 (0.8–17.1)
Hand-Foot syndrome 1 2.3 (0.1–13.8)
Radiation dermatitis 8 18.6 (8.9–33.9) 4 9.3 (3.0–23.1)
Nausea and vomiting 3 7.0 (1.8–20.2)
Diarrhea 5 11.6 (4.3–25.9) 1 2.3 (0.1–13.8)World Journal of Surgical Oncology 2009, 7:52 http://www.wjso.com/content/7/1/52
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Table 5: Phase II studies of capecitabine chemoradiation regimens in patients with LARC










De Bruine et al 
[10]
60 Pelvic RT(2 Gy/day, total 
50 Gy) +C (825 mg/m2 
b.i.d. on radiotherapy 
days) ×5 weeks
67 pCR (13) 50 Grade 3 diarrhea 
(2%), radiation 
dermatitis (3%).
De Paoli et al 
[21]
53 Pelvic RT (1.8 Gy/day, 
total 45 Gy) + presacral 
boost(3 × 1.8 Gy) + C 
(825 mg/m2 b.i.d.), 7-
days/week
57 pCR (24) 59 Grade 3 leucopenia 
(4%), hand-foot 
syndrome (4%).
Dunst et al [22] 69 (efficacy)
63 (safety)
Pelvic RT (1.8 Gy/day) + 
presacral boost(3 × 1.8 
Gy) + C (825 mg/m2 
b.i.d.), ×6 weeks
73 pCR (4) NR Grade 3 leuko-/
lymphocytopenia 
(10%), diarrhea (4%),
Dunst et al [23] 96 Pelvic RT (50.4–55.8 Gy, 
conventional 
fractionation) + C 
(825 mg/m2 b.i.d.)





Dupuis et al [24] 51 Pelvic RT (1.8 Gy/day, 
total 45 Gy) + C (825 
mg/m2 b.i.d.), 7-days/
week
58 pCR (20) 58 Grade 3 diarrhea 
(12%), radiation 
dermatitis (8%).
Kim et al [25] 38 Pelvic RT (1.8 Gy/day) + 
presacral boost(3 × 1.8 
Gy) + C (825 mg/m2 
b.i.d.) + LV (20/m2/day) 
days 1–14, 2 cycles of 14 
days.




Lin et al [26] 53 (efficacy)
52 (safety)
Pelvic RT (1.8 Gy/day, 
total45 Gy) + primary 
tumor/perirectal node 
RT(1.75 Gy/day, total 
52.5 Gy) + C(825 mg/m2 
b.i.d.) ×5 weeks
62 pCR (17) NR Grade 3 diarrhoea 
(13%), radiation 
dermatitis (6%)
Velenik et al [27] 57 Pelvic RT (1.8 Gy/day, 
total 45 Gy) + C (825 
mg/m2 b.i.d.), 7-days/
week
49 pCR (9) 65.5 Grade 3 dermatitis 
(34.5%), diarrhoea 
(3.6%),
Present study 43 Pelvic RT (1.8 Gy/day, 
total 45 Gy) +C (825 mg/
m2 b.i.d. on radiotherapy 
days) ×5 weeks
74 pCR (9) 46.5 Grade 2 anemia(9%) 
leucopenia(5%), 
diarrhoea (4%) Grade 
1 hand-foot syndrome 
(2%).World Journal of Surgical Oncology 2009, 7:52 http://www.wjso.com/content/7/1/52
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with pathologically determined complete response rate
(ypT0N0 disease) of 9.3% (4 out of 43 patients). The
downstaging rate in the present study is comparable to
those in most of phase II studies of chemoradiation regi-
mens where the downstaging rates ranged from 58% to
73% [10,21-26]. On the other hand, our figure is much
higher than that reported by Velinik et al., [27] (49%).
The main reason for the lower downstaging rate in the
reported study could be the prolonged radiotherapy
course in 45.5% of patients with treatment interruptions
of 3 days or more introduced in 18% of them. The patho-
logical complete response rate, ranged from 4 to 31% in
most of the reported studies [10,21-27]. The pathological
complete response rate in the current study (9%) is com-
parable with those found by Dunst et al, [22](4%), Dunst
et al, [23](7%), and Velenik et al, [27] (9%). On the other
hand, it is lower than that reported by De Bruin et
al.[10](13%), De Paoli et al,[21] (24%), and Kim et al,
[25](31%). The higher figures in the reported studies than
that in the present study may be due to more favorable
distribution of T stage [10,21] or the use of radiation
boost to tumor as well as use of leucovorine in addition to
capcitabine [25]. In the subgroup of our patients, with
unresectable rectal cancer (10 patients with T4N1 disease),
the resectability rate was 60% (6 out of 10 patients). The
unresectable 4 cases were one patient with persistent sac-
ral infiltration and 3 cases with peritoneal deposits diag-
nosed during exploration. The resectability rate in those
patients is comparable with that found by Veditic et
al.[28] (62%) and lower than that reported by Glimelius
et al.[29](71%). The use of methotrexate, 5-FU and leu-
covorine as the chemotherapy regimen, in the reported
study, may explain their higher figure of resectability rate
[29].
In the present study, complete response to chemoradio-
therapy resulted in favorable tumor and nodal stage.
However, despite a complete regression of the mural
tumor, the mesorectum can harbor residual cancer depos-
its. Therefore, even those in whom a complete response is
suspected should undergo standard excisional surgery
[30].
The sphincter preservation rate, in the present study, was
46.5% (20 out of 43 patients). The reported sphincter
preservation rates ranged from 50% to 72% [10,21,23-
25,27]. These higher rates in the reported studies than that
in the current study, may be due to higher radiotherapy
dose (50 Gy)[10,25], capcitabine administration through-
out the radiotherapy period including weekends
[21,23,24], the more favorable distribution of T
stage,[25,27] or the use of leucovorine in addition to
capcitabine in the chemotherapy regimen.[25]
Sphincter preservation was achieved in the majority of
patients with initial tumor located 5 – ≤ 10 cm from anal
verge (55.6%) and in only 5 out of 16 patients (31.3%)
with tumor located <5 cm from anal verge. This is in
agreement with De Bruin et al.[10] who found a sphincter
preservation rate of 25% in patients with initial rectal can-
cer <5 cm from anal verge compared to 65% in tumors 5
– 10 cm from anal verge. However, many authors stated
that the decision to perform radical surgery (APR) should
not be changed even when downstaging occurs. Between
1999 and 2002, 316 patients from 19 institutions were
enrolled. [31] The sphincter preservation rate was 61% in
the 5 × 5 Gy radiotherapy arm and 58% in the radioche-
motherapy arm, p = 0.57. Despite significant downsizing,
chemoradiation did not result in increased sphincter pres-
ervation rate in comparison with short-term preoperative
radiotherapy. The surgeons' decisions were subjective and
based on pre-treatment tumour volume at least in clinical
complete responders [31].
No hematological grade 3 or 4 toxicities occurred. Grade
II anemia occurred in 9.3% and grade II leucopenia in
4.7% of patients. Hand-foot syndrome occurred only in
one patient at the end of the treatment and required no
treatment interruption. Grade II radiation dermatitis and
diarrhea occurred in 9.3% and in 2.3% of patients respec-
tively. The incidence of acute toxicity in the present study
is obviously lower than other phase II trials using capcit-
abine, where 4–16% grade 3 leucopenia [21-23], 2%
grade 4 anemia and neutropenia [32], 4–12% grade 3
hand-foot syndrome [21,23,25] and 2–13% grade 3
diarrhea [10,21-27] and 2–34.5%% grade 3 radiation der-
matitis [10,24-27] were reported. These differences can be
explained on the ground of use of presacral boost [21-
23,25,26] and capecitabine administration. In the present
study, because of the two-day resting period every 5 days
(i.e. capecitabine was given on radiation days only), tox-
icity might therefore be lower than that in the reported
series, where capecitabine was administered twice daily,
seven days a week.[10,21-27]
Conclusion
Despite statements by other authors that chemoradiation
did not result in increase sphincter preservation rate, our
study showed a 74.4% downstaging rate and 46.5%
sphincter preservation rate. Therefore, preoperative chem-
oradiation using capecitabine (825 mg/m2 twice a day)
may be applied to patients with locally advanced low
lying rectal cancer for downstaging and facilitate sphincter
preservative surgery. Further studies with longer follow up
period are recommended to assess the effect of this proto-
col on survival.World Journal of Surgical Oncology 2009, 7:52 http://www.wjso.com/content/7/1/52
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